Open AccessGenomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Author(s) -
Sebastian Michels,
Carina Heydt,
Bianca van Veggel,
Barbara Deschler-Baier,
Núria Pardo,
Kim Monkhorst,
Vanessa Rüsseler,
Jan Stratmann,
Frank Griesinger,
Susanne Steinhauser,
Anna Kostenko,
Joachim Diebold,
Jana Fassunke,
Rieke Fischer,
Walburga Engel-Riedel,
Oliver Gautschi,
Eva Geissinger,
Stefan Haneder,
Michaela A. Ihle,
HansGeorg Kopp,
Adrianus J de Langen,
Alex Martinez-Martí,
Lucia Nogová,
Thorsten Persigehl,
Dennis Plenker,
Michael Puesken,
Ernst Rodermann,
Andreas Rosenwald,
Andreas H. Scheel,
Matthias Scheffler,
Werner Spengler,
Ruth SeggewissBernhardt,
Johannes Brägelmann,
Martin Sebastian,
Bart Vrugt,
Martin Hellmich,
Martin L. Sos,
Lukas C. Heukamp,
Enriqueta Felip,
Sabine MerkelbachBruse,
Egbert F. Smit,
Reinhard Büttner,
Jürgen Wolf
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00210
Subject(s) - lung cancer , epidermal growth factor receptor , tyrosine kinase inhibitor , cancer research , tyrosine kinase , growth factor receptor , receptor tyrosine kinase , biology , receptor , medicine , oncology , cancer
Third-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs in EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation EGFR TKIs and their impact on treatment outcomes.